Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Apnimed, Inc. (Nasdaq: APMD) closed its upsized IPO on August 3, 2026, raising $220.8 million gross proceeds by selling 13.8 million shares at $16.00 per share, including full exercise of underwriters' overallotment option. The late-stage clinical pharmaceutical company is focused on developing novel oral therapies for sleep-related breathing diseases, with its lead candidate AD109 having completed two Phase 3 trials for obstructive sleep apnea treatment and a PDUFA goal date of February 28, 2027.